Please assess the completion status of the following clinical trial:

Trial Title: Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed HCC (or fulfilling AASLD criteria for HCC diagnosis in HBsAg positive subjects with cirrhosis in case biopsy is not feasible)~2. Disease must not be amenable to potentially curative surgery~3. Without prior systemic nor transarterial treatment~4. Prior surgery or local therapy is allowed but the target lesion must have not been previously treated~5. Child-Pugh stage A liver function~6. ECOG performance 0-2~7. Life expectancy longer than 12 weeks~8. At least one measurable treatment lesion according to modified RECIST criteria~9. Adequate haematological, hepatic and renal function~Exclusion Criteria:~1. Contra-indications to TACE treatment:~   * Main portal vein thrombosis or occlusion~  * Evidence of biliary obstruction~  * Presence of extra-hepatic disease~2. Diffuse-type HCC~3. Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment.~4. Any form of prior transarterial therapy or systemic therapy for HCC.~5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors or CYP3A4 or CYP1A2 inducers.~6. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.~7. Any haemorrhage or bleeding event of CTCAE Grade 3 or more within 4 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE+Axitinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).